New principles of diagnosis and classification of the Ehlers-Danlos syndrome

Cover Page

Cite item

Full Text

Abstract

Ehlers-Danlos syndrome (EDS) is a heterogeneous group of monogenic diseases caused by a violation of collagen metabolism, the structure and function of myomatrix and the synthesis of proteoglycans. This pathology is characteri zed by hyperelasticity of the skin, subcutaneous globules, overextension of the joints, tissue vulnerability and hemorrhagic syndrome. EDS is one of the seven hereditary connective tissue disorders for which international diagnostic criteria are met. More than 30 years ago, the so-called Berlin nosology of hereditary connective tissue disorders was first compiled and approved (1986). For a long time, doctors used the “Villefranche Nosology” classification of EDS, adopted in 1998 and divided the disease into 6 types. The new criteria were published by the International Committee of Experts in 2017. In the clinical classification of EDS, 13 types with different inheritance, clinical features and biochemical defects are described. In most cases, it is inherited by an autosomal dominant type. True prevalence is unknown due to the complexity of verification and a large number of light forms, the frequency of diagnosed cases is 1 : 5000 births, severe forms are rare (1 : 100 000). Diagnosis of this syndromeis also based on the diagnostic criteria of the international classification. The lecture presents new data on classification diagnostic criteria of EDS, polymorphism of the clinical picture, genetic heterogeneity, the main principles of treatment of the disease. The new classification criteria take into account, in the main, the features of the clinical picture, they did not simplify the diagnosis, but they increased the specificity and increased the significance of the clinical and anamnestic features. The scope of the examination is determined by the presence of leading clinical signs. The genealogical examination and molecular genetic methods of diagnostics are of great importance.

About the authors

Vadim G. Arsentev

Military Medical Academy n.a. S.M. Kirov

Author for correspondence.
Email: rainman63@mail.ru

MD, PhD, Dr Med Sci, Professor, Department of Childhood Illness

Russian Federation, Saint Petersburg

Tamara I. Kadurina

North-Western State Medical University named after I.I. Mechnikov

Email: tikadurina@mail.ru

MD, PhD, Dr Med Sci, Professor of Department of Medical Genetics

Russian Federation, Saint Petersburg

Larisa N. Abbakumova

St. Petersburg State Pediatric Medical University

Email: v-abbakoumov@yandex.ru

MD, PhD, Assistant Professor, Department of Pediatrics named after Professor I.M. Vorontsov

Russian Federation, Saint Petersburg

References

  1. Аббакумова Л.Н., Арсентьев В.Г., Гнусаев С.Ф., и др. Наследственные и многофакторные нарушения соединительной ткани у детей. Алгоритмы диагностики. Тактика ведения. Российские рекомендации // Педиатр. – 2016. – Т. 7. – № 2. – С. 5–39. [Abbakumova LN, Arsentev VG, Gnusaev SF, et al. Multifactorial and hereditary connective tissue disorders in children. Diagnostic algorithms. Management tactics. Russian guidelines. Pediatrician (St. Petersburg). 2016;7(2): 5-39. (In Russ.)]. doi: 10.17816/PED725-39.
  2. Кадурина Т.И., Горбунова В.Н. Дисплазия соединительной ткани: руководство для врачей. – СПб.: ЭЛБИ-СПб, 2009. [Kadurina TI, Gorbunova VN. Connective tissue dysplasia: guidelines for doctors. Saint Petersburg: ELBI-SPb; 2009. (In Russ.)]
  3. Полиорганные нарушения при дисплазиях соединительной ткани у детей. Алгоритмы диагностики. Тактика ведения. Российские рекомендации. Ч. 2 // Вопросы детской диетологии. – 2017. – Т. 5. – № 3. – С. 53–79. [Polyorganic disorders in dysplasia of connective tissue in children. Diagnostic algorithms. Management tactics. Russian guidelines. Part 2. Problems of pediatric nutritiology. 2017;15(3):53-79. (In Russ.)]. doi: 10.20953/1727-5784-2017-3-53-79.
  4. Alazami AM, Al-Qattan SM, Faqeih E, et al. Expanding the clinical and genetic heterogeneity of hereditary disorders of connective tissue. Hum Genet. 2016;135(5):525-540. doi: 10.1007/s00439-016-1660-z.
  5. Beighton P, Paepe AD, Steinmann B, et al. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. Am J Med Genet. 1998;77(1):31-37. doi: 10.1002/(sici)1096-8628(19980428)77:1<31:: aid-ajmg8>3.0.co;2-o.
  6. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26. doi: 10.1002/ajmg.c.31552.
  7. Singh RR, Luthra R, Routbort MJ, et al. Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential. Expert Rev Precis Med Drug Dev. 2016;1(1): 109-120. doi: 10.1080/23808993.2015.1120401.
  8. Weerakkody RA, Vandrovcova J, Kanonidou C, et al. Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome. Genet Med. 2016;18(11):1119-1127. doi: 10.1038/gim.2016.14.

Copyright (c) 2018 Arsentev V.G., Kadurina T.I., Abbakumova L.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies